STOCKS TELEGRAPH

Author: ST Staff

  • The Zosano Pharma Corp. (NASDAQ: ZSAN) stock rises by 12.78% in afterhours. Here’s to know why:

    The Zosano Pharma Corp. (NASDAQ: ZSAN) stock rises by 12.78% in afterhours. Here’s to know why:

    Zosano Pharma Corp. (NASDAQ: ZSAN) stock showed a downswing by 5.00% in the last trading close whereas the stock rises in after-hours by 12.78%. There is no recent news or press release available, to be the exact reason behind this change in ZSAN stock price. On 11 March, ZSAN has announced its fourth quarter and fiscal year 2020 financial results which could might be the reason behind this up and down in Zosano Pharma stock price. Zosano Pharma Corp is a biopharmaceutical company that focuses on developing products with rapid administration of approved molecules and established safety and efficacy profiles to provide benefit to the patient whereas in the market people do not get the treatment that they need.

    Financial Results

    • ZSAN has reported a net loss of $8.1 million in the fourth quarter of 2020 as compared to $8.9 million in the fourth quarter of 2019. For full-year 2020, ZSAN stock has experienced a net loss of $33.4 million compared to $37.6 million for the full year 2019.
    • ZSAN has calculated its Research and Development expenses as $5.4 million in the fourth quarter of 2020 compared with $5.6 million for the same quarter of 2019. The decrease of $0.2 was mainly due to $0.4 million of lower employee and consulting expenses. For full-year 2020, the R&D expenses were $21.6 million compared with $25.4 million in full-year 2019.
    • General and administrative expense in the fourth quarter of ZSAN financial year was $2.6 million, while for the fourth quarter of 2019 it was $3.1million. For the full year 2020, the G&A expense was $11.2 million while it was $11.8 million for the full year 2019. The decrease of $0.5 million and $0.6 million is due to lower employee-related expenses.
    • Lastly, ZSAN recorded its cash and cash equivalents as $35.3 million which was previously calculated as $6.3 million as of December 31, 2019.

    Conclusion

    If we look closely at the financial results, ZSAN has made better progress as compared to the previous year despite the pandemic situation going on in the world. This could be a solid reason for investors to show their interest in ZSAN stock that has caused the rise in stock. Furthermore, ZSAN has signed few important agreements, one of which is with Mitsubishi Tanabe Pharma Corporation and partnerships with EVERSANA which is a promising sign for the future of Zosano Pharma Corp.

  • Aravive Inc. (ARAV) stock price going up today, here is what happened

    Aravive Inc. (ARAV) stock price remained unchanged on Tuesday, March 16, 2021, but it gained 8.13% in the after-hours trading as ARAV Stock announced its financial results for the fourth quarter and full-year ended December 31, 2020, around 4 pm on Tuesday.

    Financial Highlights

    • ARAV Revenue for the three months and twelve months ended December 31, 2020, was $5.7 million for both periods.
    • It spent $9.7 million on operating expenses in the reported quarter and $36.5 million for the whole year
    • Aravive reported a net loss of $4.0 million, $0.25 per share for the reported quarter and $30.5 million, $1.93 per share for the full year 2020.
    • ARAV had cash and cash equivalents of $60.5 million on December 31, 2021, compared to $65.1 million as of December 31, 2019.

    Corporate updates

    • FDA guided ARAV on a registrational Phase 3 trial design for AVB-500 in PROC and initiated the trial during the first quarter of 2021. The global randomized trial will enrol 300-500 patients and will evaluate the efficacy and tolerability of AVB-500 at a dose of 15 mg/kg in combination with paclitaxel vs paclitaxel monotherapy.
    • Aravive dosed its first patient in its Phase 1b/2 trial of AVB-500 in ccRCC during the first quarter of 2021. The Phase 1b portion of the trial is expected to enrol up to 18 patients in three dosing arms (15 mg/kg, 20 mg/kg and 25 mg/kg) to evaluate tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AVB-500 in combination with cabozantinib. Aravive expects to report topline data from the Phase 1b portion of the trial in the second half of 2021.
    • Aravive signed a license agreement with 3D Medicines Inc. for the development and commercialization of AVB-500 in China Hong Kong, Macau, and Taiwan. ARAV will get $12 million and is eligible to receive up to $207 million in development and commercial milestone payments and also a percentage form net sales of AVB-500 in Greater China.

    Participation in Society of Gynecologic Oncology Annual Meeting

    On March 12, 2021, ARAV announced that it is going to present updated data from its Phase 1b trial evaluating AVB-500 in platinum-resistant ovarian cancer (PROC) at the 2021 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. the meeting is scheduled to held virtually on March 19-25, 2021.

    Participation in virtual investors conferences

    Aravive, Inc. participated and conducted meeting virtually at the H.C. Wainwright Global Life Sciences Conference which took place on March 9-10, 2021.

    Aravive stock is also going to participate virtually in the Oppenheimer 31st Annual Healthcare Conference scheduled for Thursday, March 18, 2021, at 8:00 a.m. ET.

    About ARAV

    Aravive, Inc. was founded in 2008 and is based in Houston, United States. ARAV is a clinical-stage oncology company developing transformative therapeutics designed to stop the advancement of life-threatening diseases.

  • Why SG Blocks Inc. (SGBX) stock is fluctuating?

    SG Blocks Inc. (SGBX) stock faced both positive and negative trend on Tuesday, March 16, 2021. It lost 6.11% in the normal trading session but gained 8.55% in the after-hours trading on Tuesday.

    Earlier the company rescheduled the release of its financial results for the fourth fiscal quarter, which ended December 31, 2020, to after market close on March 25, 2021. The news took the stock 6.11% down on Tuesday.

    The rescheduling is announced due to the Covid outbreak in the company’s finance department which made it impossible to complete the financial review and audit.

    Subleasing COVID vaccination site to Cook Country

    On March 1 2021, SGBX announced that It has completed a sub-lease for COVID-19 vaccinations with Cook County for the former K-Mart site in Des Plaines, Illinois, a suburb outside of Chicagovia its partnership with Chicago Airport Testing LLC

    Chairman and CEO of SG Blocks Paul Galvin said that they are happy to supportCook County in stopping the spread of Covid by transitioning the space to a COVID-19 vaccination site.

    Executing the First contract for the National Housing program

    On February 26, 2021 SG Blocksannounced that has executed a contract to acquire and develop an approximately 7 acre site in Austin, Texas, through its wholly-owned subsidiary, SGB Development Corp.,the project will providea maximum of 225 condo units that will be sold at market rates.The net profit on the sale of the condo units is estimated to be more than $20 million.

    Providing Repaid Covid Testing facilities

    On February 8 2021 SGBX announced that it has started offering travellers rapid antigen testing at Los Angeles International Airport (LAX) for COVID-19 via Clarity Mobile Ventures.

    About the company

    SG Blocks, Inc. is a premier innovator, using code-engineered cargo shipping containers for safe and sustainable construction. The firm offers a product that exceeds many standard building code requirements, and also supports developers, architects, builders, and owners in achieving greener construction, faster execution, and stronger buildings of higher value.

  • NewAge, Inc. (NBEV) Stock Price Soared 9% Pre-Market: Here’s what happened

    NewAge, Inc. (NBEV) Stock Price Soared 9% Pre-Market: Here’s what happened

    New Age Beverages Corporation manufactures, advertises, and has a distribution line for healthy liquid dietary supplements and ready-to-drink (RTD) beverages. NBEV – the Colorado-based healthy supplement company is executing its plan to become the world’s leading social selling and distribution company –and has increased its stock price by over 9% pre-market. NBEV, Net Income improved $61.8 million whereas the prior year a net loss of $4.0 million took place, peaking investor interest in 2021.

    NewAge, Inc. Diversifies Into The CBD Sector

    NewAge Beverages Corporation has also incorporated CBD with their drinks revolutionizing the concept of CBD-infused liquids. The launch of their CBD beverage Noni+CBD in Japan went through their supply chain of more than 50,000 independent distributors.

    NewAge’s Noni+CBD product is the first CBD-infused beverage from any leading company to be approved by the Japanese Ministry of Health and the Japanese Narcotics Control Division for mass production and sale for the general public in the country.

    After adequate R&D the Noni+CBD product that was launched with a 50ml shot of Tahitian Noni Juice, emulsified with 25mg of concentrated CBD, and was deemed to be safe for consumption by Japanese health authorities. Hence NBEV being the pioneer for health-related CBD beverages, hold a monopolistic stance in an extremely lucrative market.

    Is NewAge (NASDAQ:NBEV) safe for investment in the long run?

    NBEV share price has increased approximately 880% higher than the last 5 years. The company has also managed its capital prudently, with debt accounting for only 24% of equity. This means that majority funding has been from its operations from equity capital, and since it has an extremely low debt obligation there is a diminished chance for investing in a loss-making company.

    Furthermore, savvy financial decisions like acquiring Aliven Inc., a Japan-based direct selling company that is anticipated to bring ~$20M in annualized net revenue has further strengthened the investor’s belief in the company as it has provided reassurance for the expansion of its portfolio.

    Conclusion

    Diversification into lucrative markets such as CBD as well as the acquisition of companies such as Aliven INC with a long term plan of increasing their supply chain and distribution network has given NBEV a major stance in the health-beverage industry and has produced a huge increase in the company valuation over the years, peaking share-holder interest for the company.

  • Almaden Minerals Ltd. (AAU) stock plunged today. Here’s why

    Almaden Minerals Ltd. (AAU) stock plunged today. Here’s why

    Almaden Minerals Ltd. (AMEX: AAU) saw a drop today by a percentage of -14.87% to the current price of $0.62. It previously closed at $0.73.

    The downward movement of the AAU stock comes along with the news of Almaden Minerals (AAU) announcing that there is a direct offering registered at $10.3 million.

    Glancing into Almaden Minerals Ltd

    Almaden Minerals Ltd (AAU) owns 100% of the Tuligtic project in Mexico. Specifically, the project covers the Ixtaca Gold-Silver Deposit that Almaden had discovered in 2010 and claimed through staking. According to Almaden’s website, the Ixtaca Deposit contains an estimated reserve of 65.1 million tons grading 1.29 million ounces of gold and 78.8 million ounces of Silver.

    15 million shares of AAU sold through direct offering

    AAU announced that it has entered into a definitive agreement with certain institutional investors for the sale and purchase of 15,846,154 shares of its common stock and common stock warrants the purchase of up to 7,923,077 shares of common stock at a combined purchase price of US$0.65 per share aggregate gross proceeds of US$10.3 million in a registered direct offering (RDO).

    What makes this offering important?

    The reason for making this registered direct offering is so that AAU can finance the preparation and submission of permit applications. These permits are required for the commencement of construction of the Ixtaca project, incremental exploratory expeditions, consulting costs and general operational costs.

    Now that Almaden Minerals Ltd (AAU) has received the capital offering, it will also resume exploration of the Ixtaca gold-silver project. Furthermore, it will be addressing the environmental permit setback that it received in December. The permit was not approved due to the requirement of additional MIA data and had been held up for 12 months awaiting a separate mineral title matter. The court that is supposed to grant the environmental permit reinstated Almaden’s original claim block despite AAU’s requesting the reduction of its land package to half.

  • Futu Holdings (FUTU) stock released its upbeat 4th Quarter Earnings results; Here’s are the details

    Futu Holdings (FUTU) stock released its upbeat 4th Quarter Earnings results; Here’s are the details

    The stock price of Futu Holdings (NASDAQ: FUTU) has increased by over 12.9% in the pre-market.

    The major news that comes adjacent to this positive stock movement is Futu Holdings (FUTU) has released its unaudited Fourth Quarter and Full Year 2020’s fiscal results.

    Largest (digital) brokerage in China

    Futu Holdings Limited is a brokerage firm, and its headquarters are based in Hong Kong. This brokerage platform is online, and access to this brokerage is accessible through the internet-device. The Futu firm is gaining massive success in China and is considered a leader in its overseas security brokerage market.

    Being a brokerage firm that is leaning towards the technology sector, Futu Holdings is making the right move of investing heavily in the research and development(R&D) of its technology as well as in analytical tools through which it also serves the role of market-news/data provider on its online platform, for the investors.

    Since the Pandemic started, the stimulus packages, reduced interest rates, and physical business restrictions had made way for the online platforms to be at the center-stage of businesses. This had the same lucrative opportunities and avenues opened for the brokerage market where the investors and consumers’ attention focused on an online-brokerage firm like Futu Holdings (NASDAQ: FUTU).

    FUTU Akin to Robin Hood

    The performance and execution of its core trade and deep-research business operations createa revenue through margin financing. It provides wealth management and investing services specifically for stock markets in the USA, Hong Kong, and China. Futu is also infamously considered the Robin Hood equivalent in China since the Chinese Government’s declaration of change in international trade relations and outlook.

    How does China’s international trade outlook benefit FUTU?

    China is opening up its trade barriers and expanding its trade relations to attract hot foreign money into its Current Account. However, the Chinese citizens are still subjected to a quota for annual foreign exchange of max $50,000. This simply means that the Chinese Government is limiting how much money flows out of the country (capital outflow).

    Fourth-quarter financials and outlook of FUTU fundamentals

    The third quarterly report indicated that FUTU had been consecutively beating its revenue estimates for four previous consecutive quarters, especially since it became Public stock in March 2019. Before releasing the fourth-quarter financial results, it already had positive expectations and strong market sentiment due to the solid backing of the FUTU’s fundamental’s performance.

    Explicitly covering the Fourth Quarter, FUTU highlighted that its total revenues had increased from 281.6% Y-O-Y to US$153 million. The total gross profit increased 321% Y-O-Y to US$121.8 million. The net income was up 11.1 times year-over-year to US$68.7 million.

    Similarly, for the Full year 2020, FUTU highlighted that the total revenues increased by 211.9% Y-O-Y to US$427 million. Total gross profit increased 253% Y-O-Y to US$337.3 million. The net income increased by over 699% Y-O-Y to US$171 million.

    The CEO of Futu Holdings (FUTU) stated that they had added more than 98,000 paying clients on a net-basis and adding a total of 320,000 paying clients in 2020. The total client asset reached HK$285.2 billion, representing more than 227% growth on a Y-O-Y basis while 41.9% growth every quarter.

    FUTU’s CFO indicated that in the fourth quarter, a significant financial investment firm purchased about 50 million Class A ordinary shares of the company in the form of prepaid warrants for an aggregated sum of US$260 million. This will be fruitful for FUTU’s current year’s capital financing balance; for investing in technological infrastructure and global marketing efforts, essentially improving the operational fundamentals for the year 2021.

  • Zomedica Corp.’s (ZOM) stock soars due to positive announcement

    Zomedica Corp.’s (ZOM) stock soars due to positive announcement

    Zomedica Corp.’s (NYSE: ZOM) stock has soared by 8.73% to the current value of $2.49.  In the after-hours market, the ZOM stock rose by %10.84.

    One of the major news that comes adjacent to the positive movement in the ZOM stock is its ability to sell its first commercial unit of the unique and valuable diagnostic tool kit. This tool kit was delivered to the veterinary market slightly ahead of the announced schedule.

    About Zomedica Corp

    ZomedicaCorp (NYSE American: ZOM) is a veterinary health company that creates commercial products for pets, specifically cats and dogs. They focus primarily on delivering and innovating products that tend to be the clinical veterinarians’ unmet needs. Market and business-wise, this is a brilliant tactic in which the Corp. stays ahead of the competition with its differentiated products that have more probability of being recommended by the clinical veterinarians.

    TRUFORMA delivered before its announced sale date

    The kit that has been tailor-made and sold is known as TRUFORMA, which was delivered ahead of the announced 30th March date. What this instrument does is that it is an on-site canine eACTHessay that is created to eliminate the risk of sample transport error. Furthermore, it aids in the diagnosis of adrenal disease.

    TRUFORMA was made true thanks to the collaboration of the employees at ZOM and a team of scientists/researchers at the Qorvo Biotechnologies LLC that worked as a development partner. Qorvo Biotechnologies, with the help of their special Bulk Acoustic Wave (BAW) radio frequency (RF) technology, can disrupt the veterinarian market with this innovative milestone in the form of veterinarian diagnostic.

    TRUFORMA sold to an established veterinary hospital

    The first official purchaser of the veterinarian diagnostic system-TRUFORMA is Jason Berg, DVM (Doctor of Veterinary Medicine), DACVIM (Diplomate, American College of Veterinary Internal Medicine). This is again a very clever marketing tactic because Jason Berg is the president and founder of Guardian Veterinary Specialists, an emergency critical care hospital located in New York. Dr. Berg is recognized professionally for his work as a veterinary internist and neurologist. Furthermore, Dr. Berg is a lecturer and a researcher who published several articles and professional journals that American Veterinary Medical Association has reviewed.

    What makes TRUFORMA so unique?

    Apart from this eACTH cortisol assay, there are two more out of the five initial assays available for commercial selling ahead of their time. T4 and endogenous ACTH are expected to be available soon while TSH, cortisol, and total T4 being commercially ready.

    This news is good for the ZOM stock’s positive movement because, in the field of clinical veterinary, vets have to depend on serum cortisol measurements to cater to adrenal diseases in dogs. With TRUFORMA’s enhanced efficacy and accuracy in cortisol assay, what is essentially going to revolutionize is how veterinarians will treat life-threatening adrenal diseases and give comforting news to the owners of the pets.

  • The FuelCell Energy Inc. (NASDAQ: FCEL) stock declines by 8.51%. Here’s what’s happening:

    The FuelCell Energy Inc. (NASDAQ: FCEL) stock declines by 8.51%. Here’s what’s happening:

    FuelCell Energy Inc. (NASDAQ: FCEL) stock show a downswing of ‎8.51‎% during the normal trading after FCEL has announced its financial results for first-quarter fiscal 2021. FCEL is an internationally renowned company for sustainable and clean energy technologies that caters few of the most critical challenges around energy, safety, and global urbanization.

    Financial Result of Q1 Fiscal 2021

    FuelCell stock price has declined after the financial results because the revenue generated is even below the expectations. Following are the details.

    1. FCEL has recorded the revenue of $14.9 million as compared to $16.3 million in Q1 fiscal 2020.

    • Service agreements and license revenue has decreased by 12% i-e $4.9 million from $5.6 million.   
    • FCEL generation revenues decreased by 10% that is $4.9 million from $5.4 million. This is due to the temporary closing of some of the Bridgeport Fuel Cell Project plants for scheduled module exchanges
    • Advanced Technologies contract revenue also declined 3% to $5.1 million from $5.2 million.

     2. FCEL in the financial results of Q1 fiscal 2021 show a gross loss of $3.6 million compared to gross profit of $3.3 million.

    3. FCEL stock recorded a loss of $14.4 million from operations as compared to $3.1 million.

    Recent Developments

    • In the first quarter fiscal 2021, FCEL managed to enter into a power purchase agreement for 2.8 megawatt project in Derby, CT in February.
    • FCEL also started operation and testing of a prototype solid oxide electrolysis hydrogen platform during the quarter.
    • The CEO of FCEL said that in this first quarter FCEL has managed to improve their balance sheet by raising capital, paying down debt executing against their core business backlog.
    • FCEL has also continued to advance their joint research with ExxonMobil Research and Engineering Company on fuel carbon capture solution.

    Conclusion

    The financial results of FCEL for Q1 fiscal 2021 are not up to the mark but FCEL’s management is working towards making it better for the shareholders. FCEL’s future plans look promising for investors.

  • Safe-T Group Ltd (SFET) stock Gains today: Here is what you need to know

    Safe-T Group Ltd (SFET) and ImageWare Systems, Inc. introduced the Zero Trust Network Access(ZTNA) Solution which is the first-ever biometric-based solution after which SFET stock price pushed by 11.66% to reach $1.82 a share today as of this writing. Safe-T stock was up by 2.52% with a $1.630 per share price at the previous closing. So here is what you need to know.

    What’s happening?

    Safe-T Group Ltd is the cybersecurity solution provider around the globe.SFET stock now has been the hot topic among investors as it has announced the availability of its joint first-ever biometric-based Zero Trust Network solution (ZTNS) between Safe-T Data A.R Ltd, a wholly subsidiary of Safe-T Group Ltd, and ImageWare Systems, Inc. that provides defense-grade biometric identification and authentication to access data related to different parameters

    ZTNA collects the data of individuals and verifies them biometrically either through cloud or on-premises in order to ensure the true identity of a person. When the user is biometrically authenticated then he/she can access the desired resource.

    Why ZTNA is needed?

    The coronavirus pandemic has changed the structure of the world in many aspects. Many businesses were shifted from offline to online. The concept of work from home or remote work has been introduced due to COVID-19. Distributed offices and remote work have risen the need for an efficient security system to secure the organizational resources as virtual private networks and passwords are no longer effective as far as organizational data security is concerned.ZTNA provides an additional layer of security by providing the features of biometric identification and restricted access to resources.

    SFET’s Earnings overview:

    SFET has announced recently that it will release its fourth-quarter and full-year financial results of 2020 on March 22, 2021, at 8:30 AM EST. SFET generated $3,591,000 revenue in the first nine months of 2020 which is 65% higher than the revenue of the same period of 2019. Third-quarter revenue reached $1,426,000 with a 6% increase as compared to the same tenure of 2019.

    Conclusion:

    SFET stock price was bullish in the previous closing and ZTNA news has added more hype to the. SFET stock price. The management is optimistic that ZTNA will prove to be the best security system for distributed offices. The safe-T stock has overall reflected significant growth over the year and fourth-quarter earnings results ahead will further decide the fate of the SFETstock.

  • Why Xunlei Limited (XNET) stock rallied in Pre-Market trading?

    Xunlei Limited (XNET) announced its unaudited fourth-quarter financial results and fiscal year 2020 results after which XNET stock price saw a jump of 12.40% to reach $8.70 a share as of this writing. XNET per share price was $7.74 at the previous closing with a 3.20% gain.Let’s deep dive to explore more of it.

    What’s happening?

    Xunlei Limited is a digital media content cloud-based platform in China.Unaudited fourth quarter and fiscal year 2020 results have added more hype to the XNET stock price today.Here is the summary of the results.

    Fourth-quarter 2020 Results:

    • Xunlei Stock reached US$50.3 million in revenue representing a 15% increase from the previous quarter.
    • US$25.9 million revenue generated from cloud computing and other internet value-added services which shows a 22% increase from the last quarter.
    • Subscription and Online advertising revenues were US$20.7 million and US$3.8 million respectively with5.5% and 27.6% increase as compared to the previous quarter.
    • Gross profit was US$26.8 million with an 18.3% increase as compared to the previous quarter while gross margin was 53.3% as compared to 51.9% of the previous quarter.
    • US$4.6 million net income was generated in the fourth quarter of 2020 while US$1.5 million of net loss was recorded in the previous quarter.
    • Diluted loss per ADS was approximately US$0.07 in the fourth quarter of 2020 while it was US$0.02 in the last quarter.

    The fiscal Year 2020 Results:

    • XNET stock generated US$186.7 million in revenue with a 3.0% increase over the year.
    • US$25.9 million revenue generated from cloud computing andIVAS representing a 6.0% increase over the year.
    • Subscription revenues were US$84.3 million with a 3.4% YoY increase while Online advertising revenues were recorded US$13.2 million with a 15.6% decrease over the year.
    • Gross profit was US$93.7million with a 16.1% increase as compared to 2019 while gross margin was 50.2% as compared to 44.5% of 2019.
    • Net loss totaled US$14.1 million in 2020 as compared to US$53.4 million net loss in 2019.
    • Diluted loss per ADS was US$0.21 in 2020 while it was US$0.79 in 2019.

    XNET stock had cash, cash equivalents, and short-term investments of US$255.1 million at the end of the fiscal year 2020 as compared to US$246.0 million at the end of the third quarter of 2020.

    Conclusion:

    XNET stock news about its earnings report has added more hype in the XNET stock price. For the first quarter of 2021, Xunlei stock has projected its revenue to be between US$53 million and US$56 million which represents 8% quarterly revenue growth. Estimated financial guidance for the first quarter of 2021 points to the further growth of Xunlie Stock. Hence it can be a good bet for investors in the future.